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SYSTEMIC MONILIASIS TREATED WITH MYCOSTATIN
CASE REPORT
RAYMOND C. V. ROBINSON, M.D., M.SC.(MED.)*
Mycostatin, derived from &reptomyces noursei, has found its greatest use in the local
treatment of vaginal moniliasis and, when administered systemically, has been found to be
capable of controlling intestinal moniliasis. Early in investigative studies, the drug was
said to be ineffective when applied as an ointment to most superficial mycoses. Pharmacolo-
gic studies showed it to be poorly absorbed from the gastrointestinal tract.
The present communication deals with the successful treatment of a patient with sys-
temic moniliasis by orally administered Mycostatin. Results in a single patient would not
usually justify a report, but a search of the literature failed to reveal other similar thera-
peutic success.
CASE REPORT
E. J. S., a 64 year old married white woman, first noticed a breaking out on her ears in
1949. Local therapy had no effect and the condition gradually spread to involve her entire
body. Itching was intense and constant. She had been known to have pernicious anemia
with subacute combined degeneration since 1948. In 1953 she was found to be infested with
Ascaris lumbricoides. She had not been seen by a dermatologist until referred to me on
September 4, 1954 with a clinical impression of subacute lupus erythematosus.
Examination at the first visit revealed an eruption consisting of well defined, scaly,
slightly infiltrated, erythematous macules. The labia were edematous and excoriated. The
lips were crusted and the tongue was fissured and swollen. The patient looked debilitated
and seemed slightly dysarthric although she was well oriented.
The initial clinical impression was systemic moniliasis. Cultures of skin scrapings and
urine were made on Sabourraud's media and at the end of 72 hours were transferred to corn
meal agar. Examination of both plates showed the typical lateral chlamydospores of Can-
dicta albicans.
On September 15, 1954, Mycostatin therapy was instituted, the patient taking three
500,000 unit tablets daily. Because of the oral involvement she was also instructed to dis-
solve 4 troches, each containing 2000 units, on her tongue. At the end of two days the dosage
was increased to four tablets and five troches daily. Five days after treatment was begun,
the cutaneous lesions were definitely improved and bladder symptoms had disappeared.
At the end of ten days there was about 50% objective improvement, and itching had stopped
except for the vulval pruritus which remained unchanged. On December 31, 1954 the patient
was instructed to use Mycostatin ointment on the vulva and in the vagina. Within three
days the vuivat itching had stopped. She has remained symptom free.
No chest films were taken, so it is not known whether pulmonary infection was present.
SUMMARY AND CONCLUSIONS
In spite of pharmacologic data showing failure of absorption of Mycostatin from the
gastrointestinal tract, this patient's skin and urinary tract infections cleared completely
on oral therapy.
The vaginal infection was unaffected by systemic administration of the drug but cleared
rapidly when local therapy was instituted.
Although results in one case are not sufficient to draw definitive conclusions, further
investigations are warranted in the treatment of systemic moniliasis with Mycostatin.
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Mycostatin was supplied through the courtesy of the Squibb Institute for Medical
Research.
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